Darapladib versus placebo after acute coronary syndrome

Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) and cardiac morbidity comparing Darapladib plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Time to first major adverse cardiovascular event. Started Nov 2009; status: completed.